Trial Profile
A prospective analysis to evaluate fingolimod safety and patient profiles in a real-world setting in Buenos Aires, Argentina.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2019
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 24 Jul 2019 Results (n=97) published in the Clinical Neuropharmacology.
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 09 Oct 2017 New trial record